Work

A Phase I Study of IMGN529, an Antibody-Drug Conjugate (ADC) Targeting CD37, in Adult Patients with Relapsed or Refractory B-Cell Non-Hodgkin’s Lymphoma (NHL)

Year: 2014

Type: article

Study design: Clinical Trial

Source: Blood

DOI: 10.1182/blood.v124.21.1760.1760

Authors: Anastasios Stathis, Arnold S. Freedman, Ian W. Flinn, Kami J. Maddocks, Steven Weitman, Jesus G. Berdeja, Alex V. Mejia, Emanuele Zucca, Rebecca Green, Angela Romanelli, Sybil H Zildjian, Rodrigo Ruiz-Soto, Lia Palomba

Institutions: Istituto Oncologico della Svizzera Italiana, Dana-Farber Cancer Institute, Sarah Cannon, The Ohio State University, The University of Texas at San Antonio Health Science Center, Memorial Sloan Kettering Cancer Center, ImmunoGen (United States)

Language: English

Topic: Lymphoma Diagnosis and Treatment

Subfield: Pathology and Forensic Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2560068851

FWCI: 2.087

Cites:

Cited by: 17

Related to: 10